An interventional study of Use of an unblinded CGM device in Obesity & Overweight, Obese Adolescents and Metabolic Abnormalities, sponsored by University of Florida. Not yet recruiting at 1 site in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by University of Florida · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Obesity by University of Florida — 5 open to participants now, 6 under way, none of them phase 3. Obesity · University of Florida.
Among the 37 studies in Obesity by University of Florida, this one is the 12th largest by planned enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2026, is one of 29 with no phase, and was the 36th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →5 of the 37 studies in Obesity by University of Florida are open now, in 1 country. Recruiting first, the newest first:
University of Florida · Sites in United States
Ages 25+ · Women only · Healthy volunteers
University of Florida · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 30–79
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 13 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 4 1
First in 2003; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 55 across the 34 interventional studies, 392 across the 3 observational. Of the 31 that completed or were terminated, 13 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Florida is the lead sponsor of 1,290 studies on the registry; 202 are open to participants now.
Of its 181 completed or terminated interventional studies of FDA-regulated products, 143 (79%) have results posted.
2 of the studies in Obesity by University of Florida that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05561595University of FloridaTransdiagnostic Intervention to Reduce Internalized Health-Related Stigma | 2026-12-31 |
| NCT07714759University of FloridaA Study Comparing Continuous Glucose Monitoring Augmented Nutritional Counseling and Standard of Care Treatment Strategies in a Three-Month Nutrition Intervention | 2027-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 37 studies in Obesity by University of Florida, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this project is to determine the feasibility of introducing CGMs to adolescent patients with obesity and pre-diabetes (Hemoglobin A1C: HbA1C between 5.7-6.5%) to determine whether their eating habits and subsequent glucose profiles are modified by the timely awareness of glucose excursions above the diabetes threshold of 200 mg/dl.
Building on prior UF protocols and national ORBIT-model guidance for early-phase behavioral-treatment development, this study represents a Phase I/IIa feasibility and signal-of-efficacy trial. The study is a comparison of food choice and decision making between a NO CGM group and a Open-label CGM group. Several bio markers are used to determine the consequences of nutritional choices. This information is used in nutritional counselling sessions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
BMI >85th and BMI \< 95th percentile for age and sex (CDC growth charts) if the risk factors below are present: Family history of type 2 diabetes in first or second degree relative:
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation:
Current or planned use of medications affecting glucose dynamics, including:
o Insulin, glucagon-like peptide-1 (GLP-1) receptor agonists, metformin, or other glucose-lowering or weight-loss medications within 6 weeks prior to enrollment or planned during the study period.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Use of a continuous glucose monitor where the patient can see all of their blood glucose data
Device: Use of an unblinded CGM device
Standard of care treatment with no CGM use
Open use of CGM device where patients can see their blood glucose values.
Total caloric intake
Total caloric intake as assessed from a validated 24-hour Dietary Recall
Time frame: Baseline; 3 Months
Total grams of carbohydrates from sugar
Total grams of carbohydrates from sugar in food as assessed from a validated 24-hour Dietary Recall
Time frame: Baseline; 3 Months
5-point Likert scale Questionnaire of child food understanding
Results from a questionnaire assessing the child's understanding of food on a 5-point likert scale
Time frame: Baseline; 3 Months
Metabolic outcome - Difference in Hba1c
Difference in Hba1c, tested per standard of care
Time frame: Baseline; 3 Months
Metabolic outcome - Difference in BMI Z score
Difference in BMI Z score, per standard of care
Time frame: Baseline; 3 Months
Metabolic outcome - Difference in complete metabolic panel
Difference in complete metabolic panel between baseline and 3 months, per standard of care
Time frame: Baseline; 3 Months
Differences in Fitness assessment scores
Difference in Fitness Assessment scores using an already published fitness assessment testing battery given to each patient
Time frame: Baseline; 3 Months
Start is estimated for Dec 2026; primary completion for Aug 2027, 8 months later.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 8 months is below that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Dec 2026, on Nov 19, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.